Mutations within the gene encoding the nuclear tumoursuppressor protein, p53, represent the commonest genetic change associated with human cancer detected to date (reviewed in Levine et al., 1991) . Although the precise function of normal p53 is not yet firmly established, it probably acts as a transcription factor in regulating gene expression during traverse of the cell cycle (see Levine et al., 1991; Lane, 1992) . Loss of p53 function through a variety of mechanisms, principally involving gene mutation and deletion, is thus thought to be an essential prerequisite for tumorigenesis in many cell types. A well-recognised property of mutant p53 protein is its prolonged half-life within the cell compared with that of its normal (wild-type) counterpart (Gannon, 1990; Levine et al., 1991) . Consequently, the cellular levels of such mutant p53 are considerably higher than those of the normal protein and mutant p53 can therefore be readily detected by a variety of immunohistochemical staining techniques (Levine et al., 1991) . Elevation of p53 levels may also occur through non-mutational mechanisms associated with enhanced stabilisation of the protein or interruption of normal degradative pathways (Levine et al., 1991) . Nevertheless, positive staining for p53 generally provides a convenient 'marker' for the presence of a mutated p53 protein, which greatly facilitates studies aimed at correlating the presence of this mutant tumour suppressor with clinicopathological features of disease.
In common with most other solid tumour types, ovarian carcinomas frequently harbour mutations in the p53 gene associated with elevated levels of protein detectable immunohistochemically on frozen tissue sections (Marks et al., 1991; Mazours et al., 1991; Eccles et al., 1992) . Interestingly, some of these studies have suggested possible prognostic correlates associated with the presence of mutated p53. Marks et al. (1991) reported a significant correlation between p53 immunocytochemical staining and tumour cell ploidy which is known to be related to tumour aggressiveness and overall survival. Independently, Okamoto et al. (1991) (Okamoto et al., 1991) .
The multidrug resistance gene, mdr-1, encodes a plasma membrane glycoprotein (P-glycoprotein or gpl70) that is expressed in both normal tissues and tumour cells (Endicott & Ling, 1989; Goldstein et al., 1989) . Murphy et al. (1992) found that 13% of ovarian tumours expressed P-glycoprotein, and recent data have shown that mutant, but not wild-type, p53 protein transactivates the promoter region of the mdr-1 gene (Chin et al., 1992) . Since drug resistance is a major clinical problem in the treatment of ovarian cancer, it is important to establish whether there is any relationship between p53 mutation and drug resistance in tumours prior to chemotherapy.
In-the study reported here we examined a series of 50 ovarian epithelial carcinomas for the presence of p53 mutation by immunohistochemical staining with the polyclonal antibody CM1 (Bartkova et al., 1991) (Shepherd, 1989) and tumour samples taken along with normal peritoneal biopsies. Forty samples were from patients undergoing initial staging laparotomy and the other ten were taken from operations for recurrent or residual tumour following chemotherapy. Samples of normal ovarian tissue were also taken from patients undergoing oophorectomy for benign gynaecological disease in the same geographical area. All material was collected and frozen immediately in liquid nitrogen prior to subsequent storage at -80°C.
The histological type and grade were assigned to each tumour by independent review by the North West Ovarian Cancer Group pathologists.
Immunohistochemistry
When required, samples were thawed and then fixed in Methacarn for 1 h at room temperature. They were then embedded in paraffin and 4 tm sections taken and mounted on Cell-Tak subbed slides and dried at 36°C overnight. The slides were initially dewaxed and air dried for 15min, then washed with 0.5 M TBS (Tris-buffered saline) at pH 7.6 before blocking endogenous peroxidase activity with 1.5 M sodium azide and 30% hydrogen peroxide. Following this the samples were again washed in TBS and exposed to a 10% solution of normal swine serum for 10 min at room temperature. They were then exposed in sequence to the primary antibody (CM1; Bartkova et al., 1991) for 1 h at 37°C, a further TBS wash, a 1:2400 solution of peroxidaseconjugated swine anti-rabbit immunoglobulin solution for 30 min at 37°C and a further TBS wash. The slides were developed using diaminobenzidine (0.5mgml-') with 0.1% nickel chloride in TBS buffer for 10 min at room temperature, followed by incubation for 10 min with the same solution with the addition of 30% hydrogen peroxidase
(1 jlI ml-'). The slides were then washed in distilled water and the silver intensification carried out as described by Przepiorka and Myerson (1986) for 1 min. The slides were finally washed three times in distilled water, counterstained for 10s in Mayer's haematoxylin, dehydrated, cleared in xylene and mounted with xylene-based coverslipping medium. The evaluation of the staining was performed by a single observer (J.R.). The tumours were designated positive if obvious staining of two or more distinct areas of cells was seen when compared with negative controls from consecutive sections. This method of assessment was chosen initially because of the known heterogeneous nature of the biopsy samples with tumour and stromal tissue present. In all cases where positive staining occurred, all tumour tissue present showed some degree of staining. However, this ranged from approximately 5% to 50% of the biopsy examined. All staining analyses were performed using negative control sections of the tumours (using 1:1000 normal rabbit serum in place of the primary antibody) in parallel with known positive control tumour.
Initially a known p53-staining breast tumour was used as a positive control to establish the technique on ovarian tumour sections. When a clearly positive-staining ovarian tumour was identified, this was then used as control for the subsequent screening of the tumour panel. This tumour was also the first one in which we identified a mutation by sequencing (tumour A, Figure 2) .
Staining for mdr status using the MRK 16 antibody was performed as described by Murphy et al. (1992) .
PCR amplification and sequencing of exons 5-8 of the p53 gene DNA was prepared from frozen biopsy samples by standard methods of detergent lysis, proteinase K digestion and phenol extraction as described previously (Deane & Norton, 1990) . PCR amplification was performed using the following primer pairs (in each case 5' and 3' primer respectively):
TTCAACTCTGTCTCCTTCCT and TTAACCCCTCCTCC-CAGAGA for exons 5 and 6, AGGCGCACTGGCCTCA-TCTT and TGTGCAGGGTGGCAAGTGGC for exon 7 and TTCCTTACTGCCTCTTGCTT and AGGCATAACT-GCACCCTTGG for exon 8. A 1 fig aliquot of genomic DNA was amplified with 1 llM of each primer in a reaction mix comprising 67 mM Tris pH 8.8, 6.7 mM magnesium chloride, 10 mM P-mercaptoethanol, 6.7 mM ethylenediaminetetracetic acid, 179 mg ml-' bovine serum albumin, 10% dimethylsulphoxide and 1.5 mM dATP, dCTP, dGTP and TTP, in a volume of 50 gil. Following denaturation at 95°C for 7 min, 1 unit of Taq polymerase (Boehringer Mannheim, Germany) was added and the mixture was overlaid with mineral oil. Thirty cycles of amplification, consisting of denaturation at 94C (1 min), annealing at 54°C (1 min) and elongation at 72°C (2 min), were followed by a final extension reaction at 72°C for 7 min. PCR-amplified DNA was purified on 1.5% low melting temperature agarose and sequenced directly on both strands, using Taq polymerase and the same primers, essentially as previously described (Deane & Norton, 1990) . Sequencing reactions were analysed on denaturing 6% polyacrylamide gels. Table I summarises the characteristics of the 50 ovarian epithelial tumours examined for p53 staining with the polyclonal antibody CM1. As negative control we examined five samples of normal ovarian tissue obtained from patients undergoing oophorectomy for benign gynaecological conditions. In addition, a further five samples of peritoneum from patients with epithelial ovarian tumours (three with p53 overexpression and two not overexpressing p53) were examined. These, together with the normal controls, were all negative for p53 staining (data not shown). Of the 50 ovarian tumours, 28 (56%) were positive for p53 staining (Table 1) . Typically the pattern of staining was nuclear localised, as exemplified in Figure la . (Bartkova et al., 1991) . Since we used CMl on Methacarn-fixed, paraffin-embedded tissue sections in our own study, it was important to show that the use of such fixed sections did not lead to a significant false-negative rate. Five tumours, all of which showed no detectable p53 staining in Methacarn-fixed tissue, were stained using frozen tissue sections and all were negative (data not shown).
Results
In order to determine whether those cases in our series expressing high levels of p53 protein also harboured mutant p53 genes, exons 5-8 of the p53 gene were sequenced on both strands using PCR-amplified DNA from four tumours expressing high levels of p53 and from one with normal (undetectable) levels of this protein. Point mutations within conserved regions of exons 7 and 8 were seen in three of these, all of which expressed elevated levels of p53 protein (Figure 2 , Table II ). Two cases shared the same mutation in codon 273 (cases A and C). In order to exclude the possibility that one or other of these mutations arose from contamination of cellular DNA with PCR products, these two cases were reanalysed by PCR and sequencing. The same mutation at codon 273 (Table II) was again seen in both cases. As can be seen in Figure 2 , all three cases with detectable p53 mutations also harboured wild-type p53 sequence consistent either with these mutations being present on one allele only or with the presence of admixed stromal cells containing only wild-type p53.
In 37 of the tumours examined, data were available on the expression of mdr-I P-glycoprotein (Murphy et al., 1992) . Of these 37, only eight were mdr positive, as determined by staining with the MRK 16 antibody. Two of these were, however, p53 negative (Table III) . A statistical analysis (Fisher's exact) showed no significant difference in mdr (gpl70) expression in p53-positive or -negative tumours.
As shown in Table I , there was no correlation between p53 overexpression and differentiation or stage of the tumours. Similarly, when the incidence of cases overexpressing p53 was compared between patients pre and post treatment, we observed no significant difference between these groups (Table I) . Although all the p53-positive cases were from FIGO stage III/IV patients, the number of stage I/II cases in this study was too low to establish the significance of this observation (Table I) . Interestingly, when the distribution of p53-positive and -negative cases was examined in the context of histological tumour type (Table I) there was a statistically significant difference (P=0.0237) between the serous and mucinous tumours. Finally, we were unable to detect significant association between p53 staining and response to chemotherapy (Table IV) .
Discussion
One objective in our studies was to establish the reliability of detecting overexpression of p53 in ovarian tumours by using the polyclonal antibody CM 1, which can be used on Methacarn-fixed sections. The frequency of p53 protein detection (56% of cases) was similar to that reported previously in published studies employing either immunohistochemistry on frozen biopsies or DNA-based methods (nucleotide sequencing or single-strand conformational polymorphism) (Eccles et al., 1991; Marks et al., 1991; Mazours et al., 1991 a different histological tumour types, a higher proportion of serous carcinomas were positive for p53 staining than were tumours of the mucinous type. This difference in incidence of p53 overexpression may well reflect subtle differences in aetiology and or epidemiology associated with these histological subtypes.
In the light of the recent report by Chin et al. (1992) documenting transactivation of the mdr gene promoter by mutant p53, we examined the relation between p53 staining and expression of the mdr-1 P-glycoprotein, determined on 37 of this series of adenocarcinomas, some of which formed part of a previous study (Murphy et al., 1992) . Because of the low frequency of expression of gpl7O in ovarian tumours we were unable to establish a significant correlation between mdr and p53 expression. However our data show that gpl7O expression can be found in the absence of p53 overexpression, indicating that mutant p53 is probably not the sole determinant of inappropriate expression of the mdr protein in ovarian tumours.
We also examined the relation between p53 staining and response to chemotherapy. The representation of p53-positive cases was not significantly different between patients who responded and those who did not, a finding also supported by the lack of increase in the proportion of tumours which stained positive for p53 following chemotherapy. These observations suggest that, while mutant p53 may well play a role in the development of mdr phenotype, there are additional factors of greater importance in determining the response to chemotherapy.
